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Not reported.
Results of the review
The annual rate of stroke with aspirin was 4.5% (range: 0.8 -13.7).
The proportions of ischaemic strokes that were fatal, major, minor, or with no residua with warfarin or ximelagatran were: fatal 8.2% (range: 8.2 -10.1), major 40.2% (range: 40.2 -41.7), minor 42.5% (range: 34.8 -42.5), and with no residua 9.1% (range: 9.1 -13.3).
The proportions of ischaemic strokes that were fatal, major, minor, or with no residua with aspirin treatment were: fatal 17.9% (range: 10.1 -17.9), major 30.0% (range: 30.0 -41.7), minor 41.0% (range: 34.8 -41.0), and with no residua 11.0% (range: 11.0 -13.3).
The RR of stroke with warfarin compared with aspirin was 0.48 (range: 0.37 -0.63).
The RR of stroke with ximelagatran compared with warfarin was 1.0 (range: 0.74 -1.31).
In patients receiving warfarin, the annual rate of intracranial haemorrhage was 0.4% (range: 0.4 -1.2), major haemorrhage 2.5% (range: 2.0 -4.0), and minor haemorrhage 35.7% (range: 30 -40).
The RR of haemorrhage with ximelagatran compared with warfarin was 0.74 (range: 0.57 -0.97).
The RR of haemorrhage with aspirin compared with warfarin was 0.59 (range: 0.50 -0.70).
The monthly rate of elevated liver function test results with ximelagatran was 1.0% (range: 0 -2) during the first 6 months and 0.08% (range: 0 -1) after the first 6 months.
The monthly risk of elevated liver function test results with warfarin was 0.035% (range: 0 -1).
The annual rate of permanent hepatic damage with ximelagatran was 0.04% (range: 0.012 -0.113).
The RR of non-stroke and non-haemorrhage death was 1.3 (range: 1.0 -1.5) for patients with atrial fibrillation, and 2.3 (range: 1.3 -3.0) for atrial fibrillation patients with a history of stroke.
The RR reduction in all-cause mortality in patients on warfarin or ximelagatran compared with aspirin was 19% (range: 0 -33).
The quality of life estimates were as follows:
for patients in healthy states, receiving aspirin 0.998 (range: 0.994 -1) and receiving warfarin 0.987 (range: 0.953 -1); for patients suffering neurological events, mild neurological event 0.75 (range: 0 -1), moderate-to-severe neurological event 0.39 (range: 0 -1), and recurrent neurological event 0.12 (range: 0 -1); and for patients suffering a major haemorrhage other than intracranial haemorrhage 0.8 (range: 0.5 -0.99).
Methods used to derive estimates of effectiveness
Utility estimates were supplemented by the authors' own assumptions and by expert opinion. To derive the quality of life estimates associated with ximelagatran treatment, the authors conducted a one-time e-mail survey of the Anticoagulation-Thromboembolism Research Consortium, a group of approximately 30 physicians involved in antithrombotic clinical management and research. Twelve of these physicians responded. Seven decision-analysts, who had published in the area of antithrombotic therapy, were also surveyed. Three of these responded. 
Estimates of effectiveness and key assumptions
The utility associated with ximelagatran treatment was 0.989 (range: 0.986 -0.991) during the first 6 months of therapy, and 0.994 (range: 0.993 -0.996) after the initial 6 months.
The utility associated with minor haemorrhage was 0.8 (range: 0.5 -0.99), liver function test elevation 0.98 (range: 0.9 -1.0) and initiation of warfarin therapy, and initiation of warfarin therapy, 0.98 (range: 0.9 -1.0).
Measure of benefits used in the economic analysis
The measure of benefits used was the quality-adjusted life-years (QALYs). The authors obtained the utility for warfarin and aspirin from a prior survey of 83 patients with atrial fibrillation. Other utility values were derived from expert opinion, or from the authors' own assumptions.
Direct costs
The resource quantities and the costs were not reported separately. However, the authors provided detailed costs, broken down by category. The direct costs included were those of the third-party payer. These comprised the costs of adverse events such as haemorrhage, stroke, TIA, intracranial haemorrhages and hepatic failure, and drug costs. The costs of a minor haemorrhage were based on remuneration for an expanded problem-focused physician visit. The costs of a major extra cranial haemorrhage were based on Medicare remuneration for the diagnosis-related group associated with gastrointestinal haemorrhage. The costs for other adverse events were calculated using the median value of published studies and Medicare remuneration. The annual costs of warfarin therapy were calculated by combining the annual prescription cost with Medicare reimbursement information. The cost of ximelagatran was based on the cost of clopidogrel and the cost of ximelagatran in Germany. The authors reported that medical costs unrelated to antithrombotic therapy, haemorrhage or neurological ischaemia were excluded as they were interested in the incremental cost-effectiveness of one option versus another, rather than the absolute costs. Discounting was necessary, as the costs could be incurred during 20 years, and was appropriately performed at a rate of 3% per annum. The study reported the average costs. The price year was 2003.
Statistical analysis of costs
The costs were treated as point estimates (i.e. the data were deterministic).
Indirect Costs
The indirect costs were not included.
Currency
US dollars ($).
Sensitivity analysis
The authors performed one-way sensitivity analyses of the variables in the decision model over their plausible ranges. In a two-way sensitivity analysis, the authors calculated the cost-effectiveness ratios of ximelagatran for combinations of stroke and intracranial haemorrhage risk. The authors also performed first-order Monte Carlo simulations, by randomly sampling 10,000 times a series of utilities from the 70 patients who had atrial fibrillation and usable utility values, and simulated outcomes using uniform distributions in all variables.
Estimated benefits used in the economic analysis
The discounted QALYs gained with each of the three strategies were 8.58 with aspirin, 9.39 with warfarin and 9.51 with ximelagatran.
generalisability of the authors' results, the authors appropriately separated the costs into different categories. The costs were derived from Medicare and the published literature. Appropriate sensitivity analyses of the costs were performed, using ranges that appear to have been appropriate. Discounting was necessary, as the costs could be incurred over a 20-year period, and was appropriately performed. Medicare reimbursements were used to proxy prices, which may not reflect the true cost of the intervention. The price year was appropriately reported, which will facilitate any possible inflation exercises.
Other issues
The authors did not compare their findings with those from other studies. As ximelagatran is a relatively new drug, it is unlikely that any other cost-effectiveness analysis had been undertaken at the time of this study. The issue of generalisability to other settings was addressed in the sensitivity analysis. The authors do not appear to have presented their results selectively, and their conclusions reflected the scope of the analysis. The authors reported a number of further limitations to their study. First, the efficacies used in the base-case were based on a randomised, controlled trial in which compliance, monitoring and follow-up were better than in general practice, hence overestimating the benefits of both anticoagulants. In addition, since ximelagatran has a shorter half-life than warfarin and aspirin, noncompliant patients taking ximelagatran may be especially susceptible to lapses in adherence. Second, extrapolations were made from the results of clinical trials lasting only 1 to 3 years, and thus did not account for the fact that rates of adverse events could vary over the long term.
